United Therapeutics Corporation Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
United Therapeutics (UTHR) PT Bumped to $203 at Wedbush Despite Top-Line Miss
April 28, 2015 12:24 PM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and lifted her price target on United Therapeutics Corp. (NASDAQ: UTHR) from $198 to $203 despite Q1 results which missed on the top line.
"Despite the revenue miss, Q1 net sales for Remodulin of $146.3MM beat consensus... More
United Therapeutics (UTHR) Tops Q1 EPS by 41c
April 28, 2015 6:18 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $2.55, $0.41 better than the analyst estimate of $2.14. Revenue for the quarter came in at $327.6 million versus the consensus estimate of $353.5 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More